Reaction
Bone Neoplasm reporting signals
As of the last recalculation, Bone Neoplasm appears in 1,070 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 20.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 9 | 20.9 | 21.0 |
| Exemestane | 22 | 20.4 | 20.4 |
| Octreotide Acetate | 30 | 19.6 | 19.6 |
| Lanreotide Acetate | 7 | 17.5 | 17.5 |
| Alpelisib | 7 | 15.7 | 15.7 |
| Cladribine | 7 | 14.3 | 14.3 |
| Cabozantinib | 32 | 13.3 | 13.3 |
| Fulvestrant | 21 | 12.6 | 12.6 |
| Imatinib | 11 | 12.2 | 12.3 |
| Everolimus | 28 | 11.0 | 11.0 |
| Posaconazole Delayed-Release | 6 | 10.7 | 10.7 |
| Ribociclib | 17 | 10.6 | 10.6 |
| Pazopanib Hydrochloride | 14 | 10.2 | 10.2 |
| Selinexor | 4 | 9.0 | 9.0 |
| Vemurafenib | 5 | 8.1 | 8.1 |
| Methadone Hydrochloride | 4 | 7.2 | 7.2 |
| Azacitidine For | 6 | 6.4 | 6.4 |
| Lapatinib | 5 | 6.3 | 6.3 |
| Enzalutamide | 16 | 5.4 | 5.4 |
| Abiraterone Acetate | 10 | 4.8 | 4.8 |
| Olaparib | 5 | 4.7 | 4.7 |